

Ref. No: FOI000744  
 From: Public  
 Date: 20/05/2023  
 Subject: researching the usage of high-cost drugs in ophthalmology

## REQUEST & RESPONSE

1. For the 4 months from January to April 2023, how many patients received the following anti-VEGF treatments for any eye condition:

Aflibercept	668
Bevacizumab	
Brolucizumab	10
Dexamethasone	33
Faricimab	18
Ranibizumab	675

2. For the patients above, how many were new to anti-VEGF therapy? Please provide the patient numbers by the treatments listed below, excluding patients who previously had any anti-VEGF therapy.

Aflibercept	164
Bevacizumab	
Brolucizumab	
Dexamethasone	<5
Faricimab	<5
Ranibizumab	104

Please note <5 has been added where the number of patients is 5 or less, this information has been redacted to protect patient confidentiality and to ensure that patients can not be identified.